Trial Profile
Phase IIb/III study of upamostat (Mesupron) in an oncology indication
Status:
Planning
Phase of Trial:
Phase II/III
Latest Information Update: 27 Nov 2017
Price :
$35
*
At a glance
- Drugs Upamostat (Primary)
- Indications Breast cancer; Pancreatic cancer; Solid tumours
- Focus Therapeutic Use
- 19 Oct 2017 According to a Heidelberg Pharma AG media release, WILEX AG changed its name to Heidelberg Pharma AG.
- 18 Jul 2013 New trial record